Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)

Currency in TRY
180.80
+6.90(+3.97%)
Closed·

GENIL Financial Summary

Key Ratios

P/E Ratio179.98
Price/Book5.28
Debt / Equity22.98%
Return on Equity3.54%
Dividend Yield0.72%
EBITDA1.45B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of TRY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.82%
Dividend Yield
0.72%
Industry Median 1.26%
Annualised payout
1.24
Paid annually
5-Years Growth
-
Growth Streak

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 103.87
(-42.55% Downside)

Earnings

Latest Release
May 09, 2025
EPS / Forecast
1.07 / --
Revenue / Forecast
3.86B / --
EPS Revisions
Last 90 days

FAQ

What were Gen İlaç ve Sağlık Ürünleri's earnings for the latest quarter?

The Gen İlaç ve Sağlık Ürünleri EPS (TTM) is 0.82. Gen İlaç ve Sağlık Ürünleri reported sales of 3,857.99, net income of 319.82, and EPS of 1.07 for the latest quarter.

What was Gen İlaç ve Sağlık Ürünleri's net income for the latest quarter?

Gen İlaç ve Sağlık Ürünleri's net income for the latest quarter was 319.82.

How did Gen İlaç ve Sağlık Ürünleri's performance compare year-over-year in the latest quarter?

The company's revenue moved from 3,867.25 in the previous quarter to 3,857.99 in the latest quarter, and net income moved from 43.63 to 319.82 compared to the previous quarter.

What is Gen İlaç ve Sağlık Ürünleri's net profit margin on a TTM basis?

Gen İlaç ve Sağlık Ürünleri's trailing twelve months (TTM) net profit margin is 1.01%.

How does Gen İlaç ve Sağlık Ürünleri's debt to equity ratio compare to industry standards?

Gen İlaç ve Sağlık Ürünleri's total debt-to-equity ratio is 22.98%.

What is Gen İlaç ve Sağlık Ürünleri's return on investment on a TTM basis?

Gen İlaç ve Sağlık Ürünleri's trailing twelve months (TTM) return on investment (ROI) is 3.54%.

Did Gen İlaç ve Sağlık Ürünleri gain or lose cash last quarter?

In the latest quarter, Gen İlaç ve Sağlık Ürünleri's net change in cash was -283.66 million.

What were Gen İlaç ve Sağlık Ürünleri's total assets and liabilities in the latest quarter?

As of the latest quarter, Gen İlaç ve Sağlık Ürünleri reported total assets of 14,201.51 million and total liabilities of 4,928.20 million.

How has Gen İlaç ve Sağlık Ürünleri's total revenue grown this year?

Gen İlaç ve Sağlık Ürünleri's total revenue was 3,867.25 in the previous quarter and 3,857.99 in the latest quarter.

What is Gen İlaç ve Sağlık Ürünleri's gross margin on a TTM basis?

Gen İlaç ve Sağlık Ürünleri's trailing twelve months (TTM) gross margin is 19.48%.

What was Gen İlaç ve Sağlık Ürünleri's revenue per share for the latest quarter?

Gen İlaç ve Sağlık Ürünleri's revenue per share for the latest quarter was 100.84.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.